Clinical trials in-a-dish for cardiovascular medicine.

Cardiovascular diseases persist as a global health challenge that requires methodological innovation for effective drug development. It then explores challenges and emerging opportunities for the implementation of 'clinical trials in-a-dish'.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Conventional pipelines relying on animal models suffer from high failure rates due to significant interspecies variation between humans and animal models.
• 2 In response, the recently enacted Food and Drug Administration Modernization Act 2.0 encourages alternative approaches including induced pluripotent stem cells (iPSCs).
• 3 Human iPSCs provide a patient-specific, precise, and screenable platform for drug testing, paving the way for cardiovascular precision medicine.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: